Cura Therapeutics

Cura Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, California. The company's core innovation is a multimodal immunotherapy platform that generates single recombinant proteins capable of engaging multiple disease pathways concurrently, with an initial focus on solid tumors. Its lead program, CT101, is positioned as a first-in-class biologic targeting immunostimulation, anti-metastasis, and anti-angiogenesis. Cura is actively seeking partnerships to advance its pipeline.

Multimodal immunotherapy platform generating single recombinant proteins that simultaneously engage immunostimulatory, anti-fibrotic, and anti-senescence activities.

Cura operates in the highly competitive immuno-oncology space, dominated by large pharma and well-funded biotechs with approved checkpoint inhibitors, cell therapies, and combination regimens. Its differentiation lies in combining multiple anti-cancer modalities into a single biologic, a approach pursued by few. In longevity, it faces competition from a growing number of biotechs targeting senescent cells with different mechanisms.